Baidu
map

骨科指南

订阅

MedSci主页 / 所有栏目 / 骨科指南

强直性脊柱炎/脊柱关节炎患者实践指南

2020-07-22 中国风湿免疫科相关专家小组（统称） 中华内科杂志.2020,59(7):511-518.

强直性脊柱炎

近年来，强直性脊柱炎（AS）/脊柱关节炎（SpA）临床专家共识或指南不断更新，但如何更好地理解与执行，患者自我参与管理是提高诊疗水平的关键环节之一。通过成立多学科专家和患者共同参与的AS/SpA患者实

中文标题：

强直性脊柱炎/脊柱关节炎患者实践指南

发布机构：

中国风湿免疫科相关专家小组（统称）

发布日期：

2020-07-22

简要介绍：

近年来，强直性脊柱炎（AS）/脊柱关节炎（SpA）临床专家共识或指南不断更新，但如何更好地理解与执行，患者自我参与管理是提高诊疗水平的关键环节之一。通过成立多学科专家和患者共同参与的AS/SpA患者实践指南工作组，开展AS/SpA病友会患者与专家共同参与的AS/SpA患者关注问题的调查，筛选出问题，采用《世界卫生组织指南制订手册》相关原则，按照国际规范流程，提出AS/SpA患者实践指南意见15条。

下载附件：
点击下载

(因为版权问题，不支持下载)

评论区 (65)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1203759, encodeId=85fa1203e59c4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34b31383304, createdName=zhoujf1978, createdTime=Fri Mar 18 11:43:13 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201080, encodeId=21c41201080aa, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Wed Mar 09 22:12:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197810, encodeId=ea8a119e810af, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68806526235, createdName=ms1000001133517890, createdTime=Sun Feb 27 20:21:54 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185391, encodeId=3891118539163, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da876471247, createdName=ms8000001884626297, createdTime=Mon Jan 17 23:57:56 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185169, encodeId=3f931185169ef, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5f36470170, createdName=ms1000001135965433, createdTime=Mon Jan 17 13:11:58 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
    2022-03-18 zhoujf1978

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1203759, encodeId=85fa1203e59c4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34b31383304, createdName=zhoujf1978, createdTime=Fri Mar 18 11:43:13 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201080, encodeId=21c41201080aa, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Wed Mar 09 22:12:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197810, encodeId=ea8a119e810af, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68806526235, createdName=ms1000001133517890, createdTime=Sun Feb 27 20:21:54 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185391, encodeId=3891118539163, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da876471247, createdName=ms8000001884626297, createdTime=Mon Jan 17 23:57:56 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185169, encodeId=3f931185169ef, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5f36470170, createdName=ms1000001135965433, createdTime=Mon Jan 17 13:11:58 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
    2022-03-09 ms9000001115066421

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1203759, encodeId=85fa1203e59c4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34b31383304, createdName=zhoujf1978, createdTime=Fri Mar 18 11:43:13 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201080, encodeId=21c41201080aa, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Wed Mar 09 22:12:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197810, encodeId=ea8a119e810af, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68806526235, createdName=ms1000001133517890, createdTime=Sun Feb 27 20:21:54 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185391, encodeId=3891118539163, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da876471247, createdName=ms8000001884626297, createdTime=Mon Jan 17 23:57:56 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185169, encodeId=3f931185169ef, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5f36470170, createdName=ms1000001135965433, createdTime=Mon Jan 17 13:11:58 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
    2022-02-27 ms1000001133517890

    受益匪浅

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1203759, encodeId=85fa1203e59c4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34b31383304, createdName=zhoujf1978, createdTime=Fri Mar 18 11:43:13 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201080, encodeId=21c41201080aa, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Wed Mar 09 22:12:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197810, encodeId=ea8a119e810af, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68806526235, createdName=ms1000001133517890, createdTime=Sun Feb 27 20:21:54 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185391, encodeId=3891118539163, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da876471247, createdName=ms8000001884626297, createdTime=Mon Jan 17 23:57:56 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185169, encodeId=3f931185169ef, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5f36470170, createdName=ms1000001135965433, createdTime=Mon Jan 17 13:11:58 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
    2022-01-17 ms8000001884626297

    非常有用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1203759, encodeId=85fa1203e59c4, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=34b31383304, createdName=zhoujf1978, createdTime=Fri Mar 18 11:43:13 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1201080, encodeId=21c41201080aa, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b0af5475963, createdName=ms9000001115066421, createdTime=Wed Mar 09 22:12:55 CST 2022, time=2022-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1197810, encodeId=ea8a119e810af, content=受益匪浅, beContent=null, objectType=guider, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=68806526235, createdName=ms1000001133517890, createdTime=Sun Feb 27 20:21:54 CST 2022, time=2022-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185391, encodeId=3891118539163, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=da876471247, createdName=ms8000001884626297, createdTime=Mon Jan 17 23:57:56 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185169, encodeId=3f931185169ef, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=106, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5f36470170, createdName=ms1000001135965433, createdTime=Mon Jan 17 13:11:58 CST 2022, time=2022-01-17, status=1, ipAttribution=)]
    2022-01-17 ms1000001135965433

    学习

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

2019 ACR/SAA建议：强直性脊柱炎和非放射学中轴型脊柱关节炎的治疗（更新版）

美国风湿病学会(ACR,American College of Rheumatology) · 2019-08-22

风湿免疫疾病超药品说明书用药专家共识之三—强直性脊柱炎

广东省药学会 · 2016-12-12

2016 NICE技术评估指南：Secukinumab用于非甾体类抗炎药或TNF抑制剂治疗后强直性脊柱炎活动期的治疗（TA407）

暂未更新 · 2016-09-28

2016 BSR/BHPR指南：生物制剂治疗中轴脊椎关节炎（包括强制性脊柱炎）

英国风湿病学会(BSR,British Society for Rheumatology) · 2016-08-29

依那西普治疗类风湿关节炎和强直性脊柱炎的专家建议(2013)

中国风湿免疫科相关专家小组（统称） · 2013-05-14

2012 强直性脊柱炎的诊断与治疗骨科专家共识

中国骨科相关专家小组（统称） · 2012-09-01

拓展阅读

2010 依那西普治疗类风湿关节炎和强直性脊柱炎的专家建议

中国风湿免疫科相关专家小组（统称） · 2010-06-30

2010版 强直性脊柱炎诊断及治疗指南

中华医学会风湿病学分会(CRA,Chinese Rheumatology Association) · 2010-08-01

2010年更新的ASAS/ EULAR对强直性脊柱炎的治疗指南意见

国际评估强直性脊柱炎工作组(ASAS,ASsessment in Ankylosing Spondylitis international Society) · 2011-01-01

2011 NICE 强直性脊柱炎--戈利木单抗用药指南

英国国家卫生与临床优化研究所(NICE,National Institute for Health and Clinical Excellence) · 2011-08-24

2012 强直性脊柱炎的诊断与治疗骨科专家共识

中国骨科相关专家小组（统称） · 2012-09-01

依那西普治疗类风湿关节炎和强直性脊柱炎的专家建议(2013)

中国风湿免疫科相关专家小组（统称） · 2013-05-14

Baidu
map
Baidu
map
Baidu
map